Navigation Links
Hypertension and cholesterol medications present in water released into the St. Lawrence River
Date:1/26/2009

This press release is available in French.

Montreal, January 26, 2009 A study conducted by Universit de Montral researchers on downstream and upstream water from the Montreal wastewater treatment plant has revealed the presence of chemotherapy products and certain hypertension and cholesterol medications.

Bezafibrate (cholesterol reducing medication), enalapril (hypertension medication), methotrexate and cyclophosphamide (two products used in the treatment of certain cancers) have all been detected in wastewater entering the Montreal treatment station. However, only bezafibrate and enalapril have been detected in the treated water leaving the wastewater treatment plant and in the surface water of the St. Lawrence River, where the treated wastewater is released.

This study was conducted due to the sharp rise in drug consumption over the past few years. In 1999, according to a study by IMS Health Global Services, world drug consumption amounted to $342 billion. In 2006 that figure doubled to $643 billion. A significant proportion of the drugs consumed are excreted by the human body in urine and end up in municipal wastewater. Chemotherapy products, such as methotrexate, are excreted by the body practically unchanged (80 to 90 percent in their initial form).

Chemotherapy for fish?

The pharmaceutical compounds studied were chosen because of the large quantities prescribed by physicians. "Methotrexate and cyclophosphamide are two products very often used to treat cancer and are more likely to be found in water," says Sbastien Sauv, a professor of environmental chemistry at the Universit de Montral. "Even though they treat cancer, these two products are highly toxic. This is why we wanted to know the extent to which the fauna and flora of the St. Lawrence are exposed to them."

Method and quantities

Professor Sauv's team validated a rapid detection method (On-line SPE-LC-MS/MS ) (1) for pharmaceutical compounds under study in the raw and treated wastewater of the Montreal wastewater treatment plant.

The quantities of bezafibrate and enalapril detected in the raw wastewater, treated wastewater and surface water at the treatment station outlet are respectively 50 nanograms per litre, 35 ng L and 8 ng L for bezafibrate and 280 ng L, 240 ng L and 39ng L for enalapril.

"All in all, these quantities are minimal, yet we don't yet know their effects on the fauna and flora of the St. Lawrence," Professor Sauv explains. "It is possible that some species are sensitive to them. Other ecotoxicological studies will be necessary. As for the chemotherapy products detected in the raw wastewater but not in the treated wastewater, one question remains: did we not detect them because the treatment process succeeded in eliminating them or because our detection method is not yet sophisticated enough to detect them?"

A new threat to the aquatic environment

The release locations of wastewaters treated by the treatment stations are the main source of drug dispersion into the environment. Because of their high polarity and their acid-base character, some of the pharmaceutical compounds studied have the potential to be transported and dispersed widely in the aquatic environment. In Montreal, the wastewater treatment station treats a water volume representing 50 percent of the water treated in Quebec and has a capacity of about 7.6 million cubic metres per day, making it the largest physicochemical treatment station in the Americas. This is why it is important to develop a simple, rapid, precise and inexpensive method, Professor Sauv points out.


'/>"/>

Contact: Julie Gazaille
j.cordeau-gazaille@umontreal.ca
514-343-6796
University of Montreal
Source:Eurekalert

Related biology news :

1. Hypertension develops early, silently, in African-American men
2. Severe gestational hypertension may protect against testicular cancer
3. Hypertension disparity linked to environment
4. Blood pressure response to daily stress provides clues for better hypertension treatment
5. A single mechanism for hypertension, insulin resistance and immune suppression
6. Hypertension treatment effective in reversing vascular damage
7. Rare genetic mutations protect against hypertension
8. Researchers discovery may lead to hypertension treatment
9. Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension
10. Understanding hypertension in African Americans proves elusive
11. New genes present drug targets for managing cholesterol and glucose levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology: